CervoMed Inc.

CervoMed Inc.

CRVO·NASDAQ

$5.50

-0.36%
HealthcareBiotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$50.89M
EPS-2.0200
P/E Ratio-1.16
Earnings Date03/16/2026

crvo

Research Development Expenses

Last Annual Value

18.80M

3-Year CAGR

30%

5-Year CAGR

23%

10-Year CAGR

21%

CervoMed Inc.

CervoMed Inc. Competitors Analysis of research-development-expenses

CRVO · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
18.80M
30.6%17.2%11.6% 
3.78M
-34.4%-28.5%N/A
11.90M
-51.8%-37.9%-10.3%
2.84M
-4.1%5.5%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
99.13M
-2.2%15.2%32.5%
CLNN logo
Clene Inc.
NASDAQ:CLNN
14.01M
-19.3%-13.2%N/A
44.83M
2.4%4.9%N/A
4.94M
-29.5%20.2%32.2%
16.26M
23.0%164.1%N/A
69.88M
8.6%14.1%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
201.58M
43.6%32.8%21.7%
CervoMed Inc.

CervoMed Inc. Fair Value Envelope

CRVO · NASDAQ

Our analysis suggests that CRVO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.5, this represents a potential HIDDEN relative to our calculated worth for CervoMed Inc..

Intrinsic Value
Current Price: $5.5